474 results on '"Overwijk, Willem W"'
Search Results
2. Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15
3. A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy
4. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
5. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity
6. A combined radio-immunotherapy regimen eradicates late-stage tumors in mice.
7. Correction: IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma
8. Consensus nomenclature for CD8+ T cell phenotypes in cancer
9. LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade
10. Chemical Castration of Melanoma Patients Does Not Increase the Frequency of Tumor-specific CD4 and CD8 T Cells After Peptide Vaccination
11. A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy
12. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor
13. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
14. An Autologous Oral DNA Vaccine Protects against Murine Melanoma
15. Vaccination with a Recombinant Vaccinia Virus Encoding a "self" Antigen Induces Autoimmune Vitiligo and Tumor Cell Destruction in Mice: Requirement for Cd4 + T Lymphocytes
16. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy
17. Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
18. Supplementary Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
19. Supplementary Figure Legends from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
20. Supplementary Tables 1 - 11 from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
21. Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
22. Supplementary figure legends from IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation
23. Supplementary Figures 1 - 13 from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
24. Supplementary Figures 1 through 11 from IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation
25. Supplementary Methods, Figure Legends, Tables S1 - S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
26. Supplementary Figure S7 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
27. Data from IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation
28. Data from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
29. Supplementary Materials and Methods from IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation
30. Data from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
31. Supplementary Figure 5 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
32. Supplementary Figure 3 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
33. Supplementary Table 1 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
34. Supplementary Figure 2 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
35. Figure S3. Immune suppressive MDSCs and regulatory T cell percentages in parental and anti-PD-1 resistant tumor models. from Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
36. Supplementary Figure 1 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
37. Supplementary Table 5 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
38. Figure S4. The effect of blocking type I IFN on tumor cells and tumor-infiltrating lymphocytes. from Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
39. Supplementary Table 2 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
40. Supplementary Figure 2 from BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
41. Supplementary Figure 9 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
42. Supplementary Table 3 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
43. Supplementary Figure Legend from BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
44. Supplementary Table 4 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
45. Supplementary Figure 7 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
46. Supplementary Figure Legend from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
47. Data from Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
48. Movie 1 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
49. Movie 2 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
50. Supplementary Figure 5 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.